(CAR)–T cells directed against EGFRvIII tharapy (Providence Therapeutics)

N/A

Report date: 2025/05/20 17:40:09

Base Information

Drug Name(CAR)–T cells directed against EGFRvIII tharapy (Providence Therapeutics)
Drug Alias NameN/A
ClassificationVaccines > Development/production technology > Nucleic acid vaccine > RNA vaccine
Mechanisms of ActionImmunostimulantsEpidermal growth factor receptor variant III modulators
TargetsEpidermal growth factor receptor variant III
Therapy Area/IndicationsGlioblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesProvidence Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesProvidence Therapeutics Holdings Inc
Inactive CompaniesN/A
Active IndicationsGlioblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A